RGNX Looks 33.1% Undervalued on GF Value™ Despite Possible Value Trap

Regenxbio Inc (RGNX) is set to report its Q2 earnings, with analysts forecasting a significant year-over-year revenue increase despite caution reflected in recent estimate revisions. While GuruFocus's GF Value™ suggests RGNX is 33.1% undervalued, its GF Score™ of 60 highlights weak financial strength and profitability due to ongoing losses and high debt. Investors are advised to consider the mixed signals from insider selling and cautious institutional sentiment alongside potential revenue growth.